In this investor webinar from June 1st, 2022, Emyria Managing Director and CEO Michael Winlo presents an overview of the Phase 1 trial data for EMD-RX5, our proprietary ultra-pure CBD capsule and novel MDMA-analogue drug discovery pipeline.

Watch: